An update on the current pharmacotherapy for endometrial cancer

References

• Eifel PJ. Treatment of endometrial cancer. Pelvic cancer surgery. London: Springer; 2015. p. 315–325.
   Google Scholar
• Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol. Future Medicine; 2014;10:2561–2568.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. Wiley Online Library; 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Editorial. Adamkeiwicz on the nature and treatment of cancer. JAMA. 1893;XX:399–402.
   Google Scholar
• Boldt HJ. The treatment of cancer of the uterus when too far advanced for cure by extirpation of the uterus. JAMA. American Medical Association; 1909;LIII:1883–1887.
   Google Scholar
• Clark JG. Results obtained by the use of radium in the treatment of cancer of the uterus: at the University of Pennsylvania Hospital. Ann Surg. 1916;64:602–61.2.
   PubMedGoogle Scholar
• Bowing HH, Fricke RE. Results obtained in the treatment of carcinoma of the cervix uteri with radium and roentgen rays from 1915 to 1924, inclusive. Radiology. 1930;14:211–216.
   Google Scholar
• Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med. 1961;264:216–222.
   PubMed Web of Science ®Google Scholar
• Cohen CJ. Treatment problems in endometrial cancer. Clin Obstet Gynecol. 1967;10:625–640.
   PubMedGoogle Scholar
• Phillips TJ, Progestogens O. Adenocarcinoma of the uterus. BJOG. Blackwell Publishing Ltd; 1966;73:487–489.
   Google Scholar
• Bruckner HW, Deppe G. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. Obstet Gynecol. 1977;50:10s–12s.
   Google Scholar
• Seski JC, Edwards CL, Herson J, et al. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. Journals.Lww.Com; 1982;59:225–228.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Vance RB, Balducci L, et al. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer. 1981;48:658–665.
   PubMed Web of Science ®Google Scholar
• Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. Elsevier; 1996;62:278–281.
   PubMed Web of Science ®Google Scholar
• Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108.
   PubMed Web of Science ®Google Scholar
• Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. Wiley Online Library; 1985;56:1452–1455.
   Google Scholar
• Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7:227–242.
   PubMed Web of Science ®Google Scholar
• Bakkum-Gamez JN, Mariani A, Dowdy SC, et al. Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy. Gynecol Oncol. 2014;132:578–584.
   PubMed Web of Science ®Google Scholar
• AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133:485–493.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Visvanathan K, Shih I-M. Bokhman’s dualistic model of endometrial carcinoma. Revisited. Gynecol Oncol. 2013;129:271–272.
   PubMed Web of Science ®Google Scholar
• Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol. 2012;124:15–20.
   PubMed Web of Science ®Google Scholar
• Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–284.
   PubMed Web of Science ®Google Scholar
• Zannoni GF, Vellone VG, Arena V, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical–pathological and immunohistochemical study. Virchows Arch. Springer-Verlag; 2010;457:27–34.
   PubMed Web of Science ®Google Scholar
• Bogani G, Liu MC, Dowdy SC, et al. Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer Res. 2015;35:683–687.
   PubMed Web of Science ®Google Scholar
• Stringer-Reasor E, Fleming G, Tsoref D, et al. Chemotherapy and/or targeted therapies for advanced endometrial cancer: time to rethink? Controversies in the management of gynecological cancers. London: Springer; 2014. p. 59–68.
   Google Scholar
• Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.
   PubMed Web of Science ®Google Scholar
• Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783–4791.
   PubMed Web of Science ®Google Scholar
• Black JD, English DP, Roque DM, et al. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health. 2014;10:45–57.
   Google Scholar
• Oshita T, Shigemasa K, Nagai N, et al. p27, cyclin E, and CDK2 expression in normal and cancerous endometrium. Int J Oncol. 2002. DOI:10.3892/ijo.21.4.737.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Marizzoni M, et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer. 2007/02/28 Ed. 2007;109:1312–1322.
   PubMed Web of Science ®Google Scholar
• Black JD, Lopez S, Cocco E, et al. Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers. Toxins. 2015;7:1116–1125.
   PubMed Web of Science ®Google Scholar
• Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65:9603–9606.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–2041.
   PubMed Web of Science ®Google Scholar
• Burke WM, Orr J, Leitao M, et al., et al.; SGO Clinical Practice Endometrial Cancer Working Group. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134:393–402.
   PubMed Web of Science ®Google Scholar
• Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477–482.
   PubMed Web of Science ®Google Scholar
• Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1–12.
   Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736–1744.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. Elsevier; 2014;132:585–592.
   PubMed Web of Science ®Google Scholar
• Lee W-L, Lee F-K, Su W-H, et al. Hormone therapy for younger patients with endometrial cancer. Taiwan J Obstet Gynecol. 2012;51:495–505.
   PubMed Web of Science ®Google Scholar
• Niwa K, Tagami K, Lian Z, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112:317–320.
   PubMed Web of Science ®Google Scholar
• Bogani G, Cromi A, Serati M, et al. Chemotherapy reduces para-aortic node recurrences in endometrial cancer with positive pelvic and unknown para-aortic nodes. Int J Gynecol Cancer. 2015;25:263–268.
   PubMed Web of Science ®Google Scholar
• Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007;107:285–291.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22:3902–3908.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. Eur Soc Med Oncology. 2003;14:441–448.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159–2166.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 2012;125:771.
   Web of Science ®Google Scholar
• Goldfinger M, Diaz I, Muggia F. Systemic treatment of endometrial cancer: what is doxorubicin’s role?. J Clin Oncol. 2014;32:2181–2182.
   PubMed Web of Science ®Google Scholar
• Taylor NP, Powell MA. Therapeutic modalities in early-stage uterine papillary serous carcinomas, carcinosarcomas, clear-cell and mixed histology carcinomas. Uterine cancer. New York (NY): Humana Press; 2009. p. 193–216.
   Google Scholar
• Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137:581–588.
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16:8–13.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106:4834–4839.
   PubMed Web of Science ®Google Scholar
• Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10:203–208.
   PubMed Web of Science ®Google Scholar
• Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001;7:892–895.
   PubMed Web of Science ®Google Scholar
• Marshall G, Howard Z, Dry J, et al. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochem Soc Trans. 2011;39:456–459.
   PubMed Web of Science ®Google Scholar
• Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288–298.
   PubMed Web of Science ®Google Scholar
• Sini P, James D, Chresta C, et al. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 2010;6:553–554.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2:53ra75.
   PubMed Web of Science ®Google Scholar
• McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010;70:5457–5464.
   PubMed Web of Science ®Google Scholar
• Mendes Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. EMBO Press; 2009;1:315–322.
   PubMed Web of Science ®Google Scholar
• Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol. 2011;8:302–306.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010;28(Suppl. 15):3002. ASCO Annual Meeting Proceedings.
   Google Scholar
• Miyabe I, Kunkel TA, Carr AM. The major roles of DNA polymerases epsilon and delta at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet. 2011;7:e1002407.
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. ASCO Meet Abstr. 2007;25:5516.
   Google Scholar
• Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 2014;134:15–19.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Centritto F, et al. Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecol Oncol Rep. 2015;12:3–4.
   PubMedGoogle Scholar
• Bellone S, Centritto F, Black J, et al. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015. DOI:10.1016/j.ygyno.2015.04.027.
   Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Hari M, Yang H, Zeng C, et al. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003;56:45–56.
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333.
   PubMed Web of Science ®Google Scholar
• Vitolo MI, Boggs AE, Whipple RA, et al. Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene. 2013;32:2200–2210.
   PubMed Web of Science ®Google Scholar
• Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27:3104–3108.
   PubMed Web of Science ®Google Scholar
• Roque DM, Ratner ES, Silasi D-A, et al. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: a retrospective review. Gynecol Oncol. 2015;137:392–400.
   PubMed Web of Science ®Google Scholar
• Reyes HD, Thiel KW, Carlson MJ, et al. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther. 2014;18:137–151.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–271.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127:345–350.
   PubMed Web of Science ®Google Scholar
• Dong P, Xu Z, Jia N, et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer. 2009;8:103.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:486–494.
   PubMed Web of Science ®Google Scholar
• Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26:4319–4325.
   PubMed Web of Science ®Google Scholar
• Guidi AJ, Abu-Jawdeh G, Tognazzi K, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 1996;78:454–460.
   PubMed Web of Science ®Google Scholar
• Doldi N, Bassan M, Gulisano M, et al. Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol. 1996;10:375–382.
   PubMed Web of Science ®Google Scholar
• Wang J, Taylor A, Showeil R, et al. Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine. 2014;68:94–100.
   PubMed Web of Science ®Google Scholar
• Saarelainen SK, Staff S, Peltonen N, et al. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol. 2014;35:4651–4657.
   PubMed Web of Science ®Google Scholar
• Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, et al. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–460.
   PubMed Web of Science ®Google Scholar
• Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: a gynecologic oncology group study. Int J Gynecol Cancer. 2012;22:s3.
   Google Scholar
• Gadducci A, Sergiampietri C, Guiggi I. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecol Endocrinol. 2013;29:811–816.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29:2259–2265.
   PubMed Web of Science ®Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:22–27.
   PubMed Web of Science ®Google Scholar
• Simpkins F, Drake R, Escobar PF, et al. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol. 2015;136:240–245.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci VL, Dizon DS, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33(Suppl. 15). ASCO Annual Meeting Proceedings. Abstract no. 5500.
   Google Scholar
• Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015. DOI:10.1038/modpathol.2015.43.
   PubMed Web of Science ®Google Scholar
• Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110:2916–2921.
   PubMed Web of Science ®Google Scholar
• Fabre C, Gobbi M, Ezzili C, et al. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2014;74:1057–1064.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Chng WJ, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125:443–448.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992;89:5321–5325.
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J. 1997;16:1647–1655.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res. 2014;87:42–59.
   PubMed Web of Science ®Google Scholar
• Llauradó M, Ruiz A, Majem B, et al. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol. 2012;358:244–255.
   PubMed Web of Science ®Google Scholar
• Teplinsky E, Muggia F. Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol. 2014;135:364–370.
   PubMed Web of Science ®Google Scholar
• Buza N, Roque DM, Santin AD. HER2/ neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138. DOI:10.5858/arpa.2012-0416-ra.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Emens LA. HER2-directed therapy for metastatic breast cancer. Oncology. 2013;27:166–175.
   PubMed Web of Science ®Google Scholar
• Jewell E, Secord AA, Brotherton T, et al. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer. 2006;16:1370–1373.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet. 2008;102:128–131.
   PubMed Web of Science ®Google Scholar
• Villella JA, Cohen S, Smith DH, et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006;16:1897–1902.
   PubMed Web of Science ®Google Scholar
• Nagumo Y, Sims AH, Muir M, et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment. Clin Cancer Res. AACR; 2011. Available from: http://clincancerres.aacrjournals.org/content/17/13/4451.short
   Google Scholar
• El-Sahwi K, Bellone S, Cocco E, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer; 2010;102(1):134–143.
   Google Scholar
• Mullen P, Cameron DA, Hasmann M, et al. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther. 2007;6:93–100.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim H-P, Im S-A, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008;272:296–306.
   PubMed Web of Science ®Google Scholar
• Groeneweg JW, Hernandez SF, Byron VF, et al. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clin Cancer Res. 2014;20:6517–6528.
   PubMed Web of Science ®Google Scholar
• Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13. DOI:10.1016/s1044-579x(02)00098-6.
   PubMed Web of Science ®Google Scholar
• Pagano M, Tam S, Theodoras A, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269. DOI:10.1126/science.7624798.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Lahav-Baratz S. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod. 2004;10. DOI:10.1093/molehr/gah084.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Horiuchi A, Kashima H, et al. Inverse correlation between Skp2 and p27Kip1 in normal endometrium and endometrial carcinoma. Gynecol Endocrinol. 2009. DOI:10.1080/09513590903215482.
   Web of Science ®Google Scholar
• Lecanda J, Parekh TV, Gama P, et al. Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium. Cancer Res. 2007;67:1007–1018.
   PubMed Web of Science ®Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8. DOI:10.1038/nrc2347.
   PubMed Web of Science ®Google Scholar
• Kamata Y, Watanabe J, Nishimura Y, et al. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J Cancer Res Clin Oncol. 2005;131. DOI:10.1007/s00432-005-0671-2.
   PubMed Web of Science ®Google Scholar
• Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res. 2010;17. DOI:10.1158/1078-0432.ccr-10-0752.
   PubMed Web of Science ®Google Scholar
• Davidovich S, Ben-Izhak O, Shapira M, et al. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res. 2008;10. DOI:10.1186/bcr2122.
   PubMed Web of Science ®Google Scholar
• Huang KT, Pavlides SC, Lecanda J, et al. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer. PLoS One. 2012;7(9):e46072.
   Web of Science ®Google Scholar
• Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol: Mech Dis. annualreviews.org; 2007. Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.pathol.2.010506.091905
   Google Scholar
• Ellenson LH, Wu T-C. Focus on endometrial and cervical cancer. Cancer Cell. 2004;5. DOI:10.1016/j.ccr.2004.05.029.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Watanabe K, Jobo T, et al. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer. 2006;16(Suppl 1):452–457.
   PubMed Web of Science ®Google Scholar
• Shiozawa T, Horiuchi A, Kato K, et al. Up-regulation of p27Kip1 by progestins is involved in the growth suppression of the normal and malignant human endometrial glandular cells. Endocrinology. 2001;142:4182–4188.
   PubMed Web of Science ®Google Scholar
• An H-J, Lee Y-H, Cho N-H, et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology. 2002;41:437–445.
   PubMed Web of Science ®Google Scholar
• Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 2001;11:263–267.
   PubMed Web of Science ®Google Scholar
• Hao B, Zheng N, Schulman BA, et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell. 2005;20:9–19.
   PubMed Web of Science ®Google Scholar
• Cardozo T, Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 2007;8(Suppl 1):S9.
   Google Scholar
• Wu L, Grigoryan AV, Li Y, et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012;19:1515–1524.
   PubMed Web of Science ®Google Scholar
• Pavlides SC, Huang K-T, Reid DA, et al. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology. 2013;154:4030–4045.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39.
   PubMed Web of Science ®Google Scholar
• Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic. Elsevier; 2014. Available from: http://www.sciencedirect.com/science/article/pii/S0090825814011585
   Google Scholar
• Swift JG, Mukherjee TM, Rowland R. Intercellular junctions in hepatocellular carcinoma. J Submicrosc Cytol. 1983;15:799–810.
   PubMedGoogle Scholar
• Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol. 1998;60:121–142.
   PubMed Web of Science ®Google Scholar
• Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.
   PubMed Web of Science ®Google Scholar
• Morita K, Furuse M, Fujimoto K, et al. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A. 1999;96:511–516.
   PubMed Web of Science ®Google Scholar
• English DP, Santin AD. Claudins overexpression in ovarian cancer: potential targets for clostridium perfringens enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci. 2013;14:10412–10437.
   PubMed Web of Science ®Google Scholar
• Kumar S, Nag A, Mandal CC. A comprehensive review on miR-200c, a promising cancer biomarker with therapeutic potential. Curr Drug Targets. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25808651
   Web of Science ®Google Scholar
• Umene K, Yanokura M, Banno K, et al. Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. Int J Oncol. 2015;46:1498–1506.
   PubMed Web of Science ®Google Scholar
• Morelli M, Scumaci D, Di Cello A, et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Int J Gynecol Cancer. 2014;24:649–658.
   PubMed Web of Science ®Google Scholar
• Cao J, Lou S, Ying M, et al. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol. 2015;93:241–250.
   PubMed Web of Science ®Google Scholar
• Traver S, Assou S, Scalici E, et al. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy. Hum Reprod Update. ESHRE; 2014;20:905–923.
   PubMed Web of Science ®Google Scholar